As illustrated in Figure 4A, TET2 (62/97; 63.9%), ASXL1 (43/97; 44.3%), and SRSF2 (39/97; 40.2%) were the most common recurrent mutations in CMML patients involving DNA methylation, chromatin modification, and RNA splicing pathways. Here, TET2 is linked to chronic myelomonocytic leukemia.